<DOC>
	<DOCNO>NCT01250834</DOCNO>
	<brief_summary>This study ass give LY2189265 time atorvastatin affect body absorbs atorvastatin .</brief_summary>
	<brief_title>LY2189265 Atorvastatin Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>Male subject female partner childbearing potential : Agree whose partner agree use two reliable method contraception time first dose 3 month last dose study drug , determine investigator . Female subject childbearing potential ( , postmenopausal permanently sterilize [ example , tubal occlusion , hysterectomy , bilateral salpingectomy ] ) require use contraception . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) follicle stimulate hormone ( FSH ) great equal 40 milliInternational Units per milliliter ( mIU/mL ) . Female subject undergone sterilization tubal ligation : Agree use male female condom use conjunction spermicidal gel , foam , cream , film suppository time screen 3 month last dose study drug . Such subject must also test negative pregnancy time enrollment . Have body mass index ( BMI ) 18.5 30.0 kilogram per square meter ( kg/m^2 ) , inclusive . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have venous access sufficient allow frequent blood sampling . Are reliable willing make available duration study willing follow study restriction Are currently enrol , discontinue within last 90 day clinical trial involve investigational drug device offlabel use drug device concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy intolerance atorvastatin . Have know allergy glucagonlike peptide1 ( GLP1 ) relate compound include LY2189265 . Are persons previously complete withdrawn study , take part study investigate LY2189265 GLP1related compound incretin mimetics within last 3 month . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure ( least 5 minute sit ) , opinion investigator , increase risk associate participate study . Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example esophageal reflux gall bladder disease , gastrointestinal disease impact absorption distribution study drug ( example , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate GLP1 analog . Have history presence thyroid disease . Show history evidence significant active neuropsychiatric disease . Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis C and/or positive hepatitis C antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Intend use overthecounter medication within 7 day prior dose prescription medication ( exception vitamin/mineral supplement and/or hormone replacement therapy ) within 14 day prior dose . Use drug know substrate , inducer , inhibitor cytochrome P450 ( CYP ) enzyme pathway phosphorylated glycoprotein ( Pgp ) within 14 day prior first dose . Have donate blood 500 mL within month prior screen . Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , subject unwilling stop alcohol consumption 48 hour Admission ( Day 1 ) discharge unit treatment period , limit alcohol intake maximum 2 units/day day screen 48 hour prior poststudy visit ( 1 unit = 12 ounce ( oz ) 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Are subject , opinion investigator , way unsuitable participate study . Are woman child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>